// App-Quantinova.ai

: An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • Yi-Hsuan Liu

  • Ya-Wen Yang

  • Megan Miller

  • May Shawi

  • Daphne Chan

  • Saakshi Khattri

  • Laura Savage

  • Wolf-Henning Boehncke

  • Chenglong Han

Medical Centers

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • Janssen Global Services, LLC, Horsham/Malvern, PA, USA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Scientific Affairs, Horsham, PA

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Leeds, Leeds, UK

  • University Hospitals and University of Geneva, Geneva, Switzerland

Locations

  • United States

  • Maldives

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved